Results 81 to 90 of about 4,655,222 (236)

Factor Xa Inhibitors [PDF]

, 2016
Factor Xa represents an attractive target for antithrombotic drugs as blockade of factor Xa permits inhibition of both the extrinsic and intrinsic coagulation pathways. Several factor Xa inhibitors, such as rivaroxaban, apixaban and edoxaban, have been approved for certain conditions, and are also in clinical development for other indications.
Eduard Shantsila, Gregory YH Lip
openaire   +1 more source

Factor Xa inhibitors

, 2009
SummaryOral factor Xa (FXa) inhibitors are a promising alternative to current anticoagulants. This paper reviews the latest developments of oral direct FXa inhibitors and focuses on those which have been approved for the prevention of venous ...
E. Perzborn
core   +1 more source

Evolutionary Mechanisms of Coagulation Factors in Cetaceans During Aquatic Adaptation

Integrative Zoology, EarlyView.
Compared with Bos taurus, T. truncatus showed shorter prothrombin time and thrombin time but prolonged activated partial thromboplastin time, indicating pathway‐specific remodeling of coagulation. Evolutionary analyses identified 18 positively selected genes and accelerated F11 evolution, while functional assays revealed increased coagulation factor ...
Wenjun Lv, Wanfei Deng, Fei Deng, Shixia Xu, Wenhua Ren   +4 more
wiley   +1 more source

Peri‐operative management of patients having day surgery: a consensus statement from the Association of Anaesthetists, British Association for Day Surgery and the Association of Paediatric Anaesthetists, Great Britain and Ireland

Anaesthesia, EarlyView.
Summary Introduction Day surgery is now recognised widely as being a vital component of modern healthcare delivery with overall day surgery rates in the UK now > 85%. Day surgery offers an enhanced experience for patients with reduced risk of postoperative complications (e.g.
Craig R. Bailey, David Bunting, Lindsay Hudman, Shivan Kanani, Kirstin May, Catalina Stendall, Rachel Tibble, Allan Xu, Matthew D. Wiles   +8 more
wiley   +1 more source

Pulmonary Embolism—A Century of Progress

ANZ Journal of Surgery, EarlyView.
Reviews a century of progress in the diagnosis, prevention, and management of pulmonary embolism; from the first successful surgical embolectomy in 1924 to advanced imaging, pharmacological thromboprophylaxis, and treatment. In the 21st century, advances include catheter‐directed thrombolysis or mechanical thrombectomy under decision‐making guidance of
D. A. Watters
wiley   +1 more source

Anticoagulant treatment: the end of the old agents?

Swiss Medical Weekly, 2012
New oral anticoagulants used as single target inhibitors of coagulation enzymes have been developed and tested in extensive trial programmes. Results of most of these trials showed non-inferior and/or superior efficacy and safety compared to ...
Lukas Graf, Dimitrios A Tsakiris
doaj   +1 more source

New oral anticoagulants: focus on currently approved oral factor Xa and thrombin inhibitors

, 2013
Several direct oral inhibitors of factor Xa and factor IIa (thrombin) are currently in clinical development. These agents may have pharmaceutical and pharmacologic advantages compared with low molecular weight heparins and vitamin K antagonists in short ...
Johnsson, H, Rickard E. Malmström, Malmström, RE, Hans Johnsson   +3 more
core   +1 more source

Targeting protein–protein interactions with reversible covalent modalities: Non‐cysteine chemistries

British Journal of Pharmacology, EarlyView.
Abstract Protein–protein interactions (PPIs) are central to diverse cellular functions, and represent a rapidly expanding class of therapeutic targets. Advancements in covalent drug design have enabled small‐molecule drugs to overcome challenges associated with engaging these targets, such as limited durations of action and difficult‐to‐drug (expansive,
Ruchira Basu, Steven Fletcher
wiley   +1 more source

Reversal of Factor Xa Inhibitors by Andexanet Alfa May Increase Thrombogenesis Compared to Pretreatment Values

Clinical and Applied Thrombosis/Hemostasis, 2019
Recombinant coagulation factor Xa (FXa), inactivated Zh-zo, also known as andexanet alfa (AA), is a modified version of human FXa that has been developed to neutralize FXa inhibitors.
Fakiha Siddiqui BDS, Alfonso Tafur MD, Lorenzo Storino Ramacciotti BS, Walter Jeske PhD, Debra Hoppensteadt PhD, Eduardo Ramacciotti MD, PhD, Omer Iqbal MD, FACC, FESC, Jawed Fareed PhD   +7 more
doaj   +1 more source

Comparison of effectiveness and safety between uninterrupted direct oral anticoagulants with and without switching to dabigatran in atrial fibrillation ablation

Journal of Arrhythmia, 2020
Introduction Recent studies have demonstrated the feasibility of uninterrupted direct oral anticoagulants (DOACs) with a temporary switch to dabigatran (“dabigatran bridge”) for atrial fibrillation (AF) ablation.
Masahide Harada, Yuji Motoike, Yoshihiro Nomura, Asuka Nishimura, Masayuki Koshikawa, Kazuhiro Murayama, Yoshiharu Ohno, Eiichi Watanabe, Hideo Izawa, Yukio Ozaki   +9 more
doaj   +1 more source